Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Cellectis S.A. (NASDAQ:CLLS) have received an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $7.00.

A number of equities analysts recently weighed in on the stock. Barclays began coverage on shares of Cellectis in a research report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Lido Advisors LLC acquired a new stake in Cellectis in the first quarter valued at about $32,000. Global Retirement Partners LLC acquired a new position in Cellectis during the 4th quarter worth approximately $34,000. Acadian Asset Management LLC increased its position in Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 26,461 shares during the period. Virtu Financial LLC purchased a new position in shares of Cellectis during the 3rd quarter worth approximately $72,000. Finally, Millennium Management LLC raised its stake in shares of Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after buying an additional 22,080 shares in the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Stock Down 2.4%

CLLS opened at $3.24 on Friday. The business has a 50 day moving average price of $3.03 and a two-hundred day moving average price of $3.38. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61. The company has a market cap of $325.10 million, a PE ratio of -4.98 and a beta of 2.92. Cellectis has a 52 week low of $2.35 and a 52 week high of $5.48.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.04. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.